Cancer treatment-induced mucositis pain: strategies for assessment and management.

Abstract:

:Mucositis pain is a major clinical problem associated with cancer treatment. Mucosal tissue injury is a dose-limiting side effect and also limits nutritional intake and oral function, resulting in weight loss and nutritional deficits for many patients. The pathophysiology of mucositis is thought to be a complex array of cytokine-mediated events, which begins with mucosal atrophy and eventually leads to the painful ulceration of the mucosa. This article reviews current research related to pain management for mucositis. Effective treatment for mucositis pain must be targeted at the various factors involved in the pain experience. Although a number of interventions aimed to prevent and treat mucositis have been studied, there is little evidence to recommend any one treatment modality. While current strategies for pain management rely on general treatment for acute pain, research developments are aimed at targeting the specific receptors and enzymes involved in mucositis. As these breakthroughs become available clinically, thorough assessment and timely directed interventions must be implemented in order to limit patient distress from mucositis. This article presents an assessment tool specific to mucositis pain, including physical, functional, and pain parameters.

journal_name

Ther Clin Risk Manag

authors

Harris DJ

doi

10.2147/tcrm.2006.2.3.251

subject

Has Abstract

pub_date

2006-09-01 00:00:00

pages

251-8

issue

3

eissn

1176-6336

issn

1178-203X

journal_volume

2

pub_type

杂志文章
  • Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy.

    abstract::The efficacy of tamsulosin at the cost of a relatively benign side effect profile has been attributed to receptor selectivity directed at the alpha(1a) and alpha(1d) adrenergic receptor subtypes. The oral-controlled absorption system (OCAS((R))) represents a drug delivery refinement that incorporates a matrix of gel-f...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s86

    authors: Neill MG,Shahani R,Zlotta AR

    更新日期:2008-02-01 00:00:00

  • Antihepatitis C virus therapy in liver transplanted patients.

    abstract::Hepatitis C virus (HCV) management in the transplant setting is still an open issue. The therapeutic strategies being addressed include: (a) pre-transplant prophylaxis (to prevent the infection of the transplanted organ); (b) post-transplant prophylaxis (to reduce the possibility of developing acute hepatitis); (c) ma...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:

    authors: Picciotto A

    更新日期:2006-03-01 00:00:00

  • Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials.

    abstract:INTRODUCTION:Available literature suggests that the advantage of animal-derived surfactants over first-generation synthetic agents derives from the presence of surface-active proteins and their phospholipid content. Here we summarize the results of clinical trials comparing animal-derived surfactant preparations with o...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s4029

    authors: Logan JW,Moya FR

    更新日期:2009-02-01 00:00:00

  • Prostanoid therapies in the management of pulmonary arterial hypertension.

    abstract::Prostacyclin is an endogenous eicosanoid produced by endothelial cells; through actions on vascular smooth-muscle cells, it promotes vasodilation. Pulmonary arterial hypertension (PAH) is characterized by elevated mean pulmonary artery pressure due to a high pulmonary vascular resistance state. A relative decrease in ...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S75122

    authors: LeVarge BL

    更新日期:2015-03-31 00:00:00

  • Emerging approaches in Parkinson's disease - adjunctive role of safinamide.

    abstract::Ongoing neuronal death in Parkinson's disease (PD) causes an altered neurotransmission of various biogenic amines, particularly dopamine. As these changes do not follow a distinct pattern, they vary individually, and are differently pronounced. As a result, a heterogeneous onset of motor and nonmotor features occurs i...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S86393

    authors: Müller T

    更新日期:2016-08-02 00:00:00

  • Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis.

    abstract::The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS). The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiol...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S55928

    authors: Elalouf O,Elkayam O

    更新日期:2015-11-19 00:00:00

  • Emerging treatment options for the management of pemphigus vulgaris.

    abstract::Pemphigus vulgaris (PV) is a life-threatening disease belonging to the pemphigus group of autoimmune intra-epidermal bullous diseases of the skin and mucosae. The therapeutic management of PV remains challenging and, in some cases, conventional therapy is not adequate to induce clinical remission. The cornerstone of P...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S142471

    authors: Kridin K

    更新日期:2018-04-27 00:00:00

  • The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level.

    abstract:OBJECTIVE:To investigate the reactivation of the hepatitis B virus (HBV) following transarterial chemoembolization (TACE) in Chinese hepatocellular carcinoma (HCC) patients with low serum HBV DNA level, and to analyze the factors related to HBV reactivation in HCC patients with low serum HBV DNA level. METHODS:From No...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S91618

    authors: Shao W,Zhang F,Cong N,Li J,Song J

    更新日期:2015-09-07 00:00:00

  • Critical appraisal and clinical utility of atosiban in the management of preterm labor.

    abstract::Preterm birth is the major cause of perinatal morbidity and mortality in the developed world, and spontaneous preterm labor is the commonest cause of preterm birth. Interventions to treat women in spontaneous preterm labor have not reduced the incidence of preterm births but this may be due to increased risk factors, ...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s9378

    authors: Sanu O,Lamont RF

    更新日期:2010-04-26 00:00:00

  • Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery.

    abstract:PURPOSE:To report two cases of chronic postoperative cystoid macular edema, resistant to topical therapy, treated with consecutive intravitreal injections of ketorolac tromethamine. METHODS:Four daily intravitreal injections of 500 μg/0.05 mL of ketorolac were given to each patient. Complete clinical examination and O...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S97342

    authors: Tsilimbaris MK,Tsika C,Kymionis GD

    更新日期:2016-02-12 00:00:00

  • Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review.

    abstract::East Asians are prone to higher systemic exposure and increased risk of bleeding compared to other races after administration of antiplatelet agent(s). The aim of this systematic review was to compare and evaluate the appropriateness of a lower dose versus standard dose of ticagrelor in East Asians. A systematic searc...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S152276

    authors: Lee YJ,Kim H,Choi J,Lee BH,Lee SY

    更新日期:2018-01-08 00:00:00

  • Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal.

    abstract::Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S140377

    authors: Proietti M,Boriani G

    更新日期:2018-08-22 00:00:00

  • Bazedoxifene for the prevention of postmenopausal osteoporosis.

    abstract::Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (SERM) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hot flushes and...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s3476

    authors: Gennari L,Merlotti D,De Paola V,Martini G,Nuti R

    更新日期:2008-12-01 00:00:00

  • Glucarpidase to combat toxic levels of methotrexate in patients.

    abstract::In January 2012, glucarpidase (Voraxaze(®)) received approval from the US Food and Drug Administration for intravenous treatment of toxic plasma methotrexate concentrations due to impaired renal clearance. Methotrexate, an antifolate agent, has been used for over 60 years in the treatment of various cancers. High-dose...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S30135

    authors: Green JM

    更新日期:2012-01-01 00:00:00

  • Review of the combined contraceptive vaginal ring, NuvaRing.

    abstract::The purpose of this review was to test contraceptive efficacy, cycle control, tolerability, and acceptability as found in the non-comparative studies with NuvaRing((R)) by those found in the randomized trials comparing NuvaRing and combined oral contraceptives (COCs). All large non-comparative studies and all relevant...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s1964

    authors: Roumen FJ

    更新日期:2008-04-01 00:00:00

  • Optimal timing for antihypertensive dosing: focus on valsartan.

    abstract::Some specific features of the 24 h blood pressure (BP) pattern are linked to the progressive injury of target tissues and the triggering of cardiac and cerebrovascular events. In particular, many studies show the extent of the nocturnal BP decline relative to the diurnal BP mean (the diurnal/nocturnal ratio, an index ...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.2007.3.1.119

    authors: Hermida RC,Ayala DE,Calvo C

    更新日期:2007-03-01 00:00:00

  • Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.

    abstract::Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercially approved by the...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S145039

    authors: Jain MD,Bachmeier CA,Phuoc VH,Chavez JC

    更新日期:2018-05-31 00:00:00

  • Secukinumab for ankylosing spondylitis and psoriatic arthritis.

    abstract::The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not respond to anti-TNFα o...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S100091

    authors: Lubrano E,Perrotta FM

    更新日期:2016-10-21 00:00:00

  • Risk of breast cancer recurrence in patients receiving manual lymphatic drainage: a hospital-based cohort study.

    abstract:BACKGROUND:This retrospective cohort study evaluated whether manual lymphatic drainage (MLD) therapy increases the risk of recurrence of breast cancer. METHODS:We analyzed 1,106 women who were diagnosed with stage 0-3 breast cancer between 2007 and 2011 and experienced remission after surgery and adjuvant therapy. The...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S79118

    authors: Hsiao PC,Liu JT,Lin CL,Chou W,Lu SR

    更新日期:2015-02-27 00:00:00

  • Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.

    abstract::Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients' quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with ...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S105189

    authors: Wang XY,Lim-Jurado M,Prepageran N,Tantilipikorn P,Wang de Y

    更新日期:2016-04-13 00:00:00

  • A new extended release formulation (OROS) of hydromorphone in the management of pain.

    abstract::Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing ...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s1124

    authors: Weinstein SM

    更新日期:2009-02-01 00:00:00

  • Dexmedetomidine reduces sevoflurane EC50 for supraglottic airway device insertion in spontaneously breathing morbidly obese patients.

    abstract::Purpose: This study aimed to assess the effect of intravenous dexmedetomidine (DEX) on sevoflurane EC50 for supraglottic airway device (SAD) insertion in spontaneously breathing morbidly obese patients. Patients and methods: Thirty-eight morbidly obese patients with a body mass index 40-57 kg/m2 who were scheduled for...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S199440

    authors: Wan L,Shao LJ,Liu Y,Wang HX,Xue FS,Tian M

    更新日期:2019-05-03 00:00:00

  • Copeptin: a new predictor for severe obstructive sleep apnea.

    abstract:INTRODUCTION:Copeptin which is the C-terminal fragment of antidiuretic hormone (ADH), is a biomarker that has been reported to be increased in various cardiovascular disorders, cerebrovascular diseases and associated with prognosis. Patients with obstructive sleep apnea syndrome (OSAS) have a tendency to develop corona...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S80779

    authors: Çınarka H,Kayhan S,Karataş M,Yavuz A,Gümüş A,Özyurt S,Cüre MC,Şahin Ü

    更新日期:2015-04-10 00:00:00

  • Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.

    abstract::Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed surfaces as a result of DNA damage. AKs have historically been characterized as being "precancerous"; however, now it is considered by many author...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S145779

    authors: Skroza N,Bernardini N,Proietti I,Potenza C

    更新日期:2018-10-04 00:00:00

  • Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.

    abstract::Paclitaxel is an anticancer agent effective for the treatment of breast, ovarian, lung, and head and neck cancer. Because of water insolubility, paclitaxel is formulated with the micelle-forming vehicle Cremophor EL to enhance drug solubility. However, the addition of Cremophor EL results in hypersensitivity reactions...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.1.2.107.62910

    authors: Scripture CD,Figg WD,Sparreboom A

    更新日期:2005-06-01 00:00:00

  • Endoscopic treatment of biliary complications in left lobe living donor liver transplantation.

    abstract:Purpose:Almost all of the publications regarding the treatment of biliary complications after liver transplantation are related to biliary complications after right lobe living donor liver transplantation (LDLT) and cadaveric liver transplantation (LT). The number of publications regarding endoscopic treatment of bilia...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S175215

    authors: Erdogan MA,Harputluoglu MM

    更新日期:2018-10-17 00:00:00

  • Treatment with Saccharomyces boulardii and Escherichia coli Nissle is safe and associated with reduced nosocomial transmission of vanB vancomycin-resistant Enterococcus faecium on an early rehabilitation ward in Germany: a retrospective analysis.

    abstract:Purpose:According to the WHO vancomycin-resistant Enterococcus faecium (VRE) belongs to the microorganisms for which new antibiotics are urgently needed. Depending on the type of vancomycin resistance vanA gene VRE is differentiated from vanB VRE and other types. In this retrospective analysis the results of VRE survei...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S179208

    authors: Borgmann S,Rieß B,Siegmund R,Werner G,Klare I

    更新日期:2019-02-27 00:00:00

  • Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.

    abstract:INTRODUCTION:Renal cell carcinoma (RCC) represents 2%-3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) in...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章,评审

    doi:10.2147/TCRM.S126910

    authors: Leonetti A,Leonardi F,Bersanelli M,Buti S

    更新日期:2017-06-30 00:00:00

  • Comparison of anterior decompression and fusion versus laminoplasty in the treatment of multilevel cervical ossification of the posterior longitudinal ligament: a systematic review and meta-analysis.

    abstract:PURPOSE:A meta-analysis was conducted to evaluate the clinical outcomes, complications, reoperation rates, and late neurological deterioration between anterior decompression and fusion (ADF) and laminoplasty (LAMP) in the treatment of multilevel cervical ossification of the posterior longitudinal ligament (OPLL). METH...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/TCRM.S100046

    authors: Liu W,Hu L,Chou PH,Liu M,Kan W,Wang J

    更新日期:2016-04-26 00:00:00

  • Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.

    abstract::Hyperphosphatemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Recent observational data has associated hyperphosphatemia with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and current dialysis presc...

    journal_title:Therapeutics and clinical risk management

    pub_type: 杂志文章

    doi:10.2147/tcrm.s1555

    authors: Mohammed IA,Hutchison AJ

    更新日期:2008-10-01 00:00:00